Example: dental hygienist

Canine Vaccines - Nobivac

Creating strong bonds through a range of leading Gray A et al (2003) Nobivac DHPPi offers protection against infection with CDV and CPV within 7 days of vaccination. Proceedings 46th BSAVA Annual Congress, Birmingham, UK, 3-6 April 2003: p. Helps J et al (2007) An injectable modified live vaccine protects young puppies against challenge with either Canine adenovirus-1 or Canine adenovirus-2 seven days after a single vaccination. Proceedings 40th Voorjaarsdagen congress, 27th-29th April 2007, Amsterdam, NL: p. Hoskins JD et al (1995) Challenge Trial of a New Attenuated Canine Parvovirus vaccine .

Creating strong bonds through a range of leading vaccines. 1. Gray A et al (2003) Nobivac® DHPPi offers protection against infection with CDV and CPV within 7 days of vaccination.

Tags:

  Vaccine, Vaccinations, Canine, Canine vaccines

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Canine Vaccines - Nobivac

1 Creating strong bonds through a range of leading Gray A et al (2003) Nobivac DHPPi offers protection against infection with CDV and CPV within 7 days of vaccination. Proceedings 46th BSAVA Annual Congress, Birmingham, UK, 3-6 April 2003: p. Helps J et al (2007) An injectable modified live vaccine protects young puppies against challenge with either Canine adenovirus-1 or Canine adenovirus-2 seven days after a single vaccination. Proceedings 40th Voorjaarsdagen congress, 27th-29th April 2007, Amsterdam, NL: p. Hoskins JD et al (1995) Challenge Trial of a New Attenuated Canine Parvovirus vaccine .

2 Journal of Veterinary Internal Medicine 9 Greenwood NM et al (1995) Comparison of isolates of Canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains. Veterinary Record 136: Horspool LJI et al (2005) A MLV vaccine pre-vents clinical signs and shedding of CPV type 2a and 2b after challenge at 36 months after vaccination. Proceedings 48th BSAVA Annual ReferencesDistemper (MLV)Parvovirus (MLV)Adenovirus type 2 (MLV)Parainfluenza (MLV)Bordetella (Modified-live)Parainfluenza (Inactivated)Bordetella (Inactivated)VaccinePresentationNobivac DHP 10 or 20 dosesNobivac DHPPi 10 dosesNobivac KC (Intranasal) 5 or 10 doses (with diluents) Nobivac Bb/Pi 20 dosesNobivac Puppy Pack20 doses Nobivac DHP + 10 doses (with diluents)

3 Nobivac KCNobivac C5 Pack20 doses Nobivac DHP + 20 doses Nobivac Bb/PiThe Nobivac Canine vaccine range comprises Vaccines and services that reflect MSD Animal Health s long experience and leadership in small animal vaccine development. A strong research commitment to small animal Vaccines ensures that the Nobivac Vaccines are of the highest quality, trusted for their efficacy and safety. The Nobivac range is manufactured locally in Bendigo, Victoria, and is supplied in recyclable VaccinesSO936congress, 7th-10th April 2005, Birmingham, UK: pp.

4 Spibey N et al (2007) Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Veterinary Microbiology 128: Bergman JGJE et al (2005) A MLV vac-cine has a duration of immunity of at least 36 months against CDV, CAV2 and CPV. Proceedings 48th BSAVA Annual congress, 7th-10th April 2005, Birmingham, UK: pp. Gore T et al (2005) Three-Year Duration of Immunity in dogs following vaccination against Canine Adenovirus Type-1, Canine Parvovirus, and Canine Distemper Virus. Veterinary Therapeutics , , Spring 2005: Gore T et al (2005) Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours.

5 Veterinary Record 156 Jacobs AA et al (2005) Protection of dogs for 13 months against Bordetella bronchiseptica and Canine parainfluenza virus with a modified live vaccine . Veterinary Record 157 Edinboro CH et al (2004) A placebo-controlled trial of two intranasal Vaccines to prevent tra-cheobronchitis (kennel cough) in dogs entering a human shelter. Preventive Veterinary Medicine 62: Jacobs AAC et al (2006) An intranasal kennel cough vaccine administered at 3 weeks of age is able to stimulate protective immunity despite the presence of passive antibody.

6 Proceedings 31st WSAVA Congress 11th - 14th October 2006, Prague: p. Data on file: Antibody, challenge and safety studies (Registration dossier, Part III, pages 22-83).14. Bergman JGHE et al (2006) Comparative trial of the Canine parvovirus, Canine distemper virus and Canine adenovirus type 2 fractions of two commercially available modified live Vaccines . Veterinary Record 159: Animal Health 91-105 Harpin Street, Bendigo East VIC 3550 Free Call: 1800 033 DHPN obivac DHPPiModified-live virus (MLV) vaccine Canine Distemper virus (CDV) Canine Adenovirus type 2 (CAV-2) Canine Parvovirus (CPV) +/ Canine Parainfluenza virus (CPi)

7 Earlier socialisation of puppies 10 week finish possible in puppies* 7 days onset of immunity*1,2 Premium parvovirus protection Patented CPV strain C-154 Breaks through MDA earlier permitting a 10 week finish in puppies Proven clinical protection and prevention of viral shedding for ALL known CPV field strains (2, 2a, 2b and 2c)3,4,5,6 Protects against clinical disease and shedding for at least 3 years for CPV-2, 2a and 2b5,7,83 years duration of immunity* Provides customised approach to vaccination supported by registered label claims Consistent with current international (WSAVA) and national (AVA)

8 Vaccination guidelines Responds to pet owner concerns about over-vaccinationSubstantial peer-reviewed published laboratory and field dataDHP compatible for concurrent use with intranasal Nobivac KC DHP can be reconstituted with Nobivac Bb/Pi to administer a single injectable C5 *For Distemper, Hepatitis and Parvovirus componentsModified-live vaccine Bordetella bronchiseptica (Bb) Canine Parainfluenza virus (CPi)Premium Canine cough protection Rapid onset of local immunity 72 hours for the Bordetella component9 At least 12 months duration of immunity10 Significantly reduces organism shedding10 Intranasal Vaccines prevent infection and decrease signs of disease compared with parenteral Vaccines that do not act locally to prevent pathogen entry11 Simple intranasal administration Low dose mL ONE nostril onlyEarlier socialisation of puppies Use from 4 weeks of age Stimulates protective immunity even in the

9 Presence of MDA12 Annual revaccinationRegistered for use in pregnant bitchesCompatible for concurrent use with Nobivac DHPI nactivated vaccine Bordetella bronchiseptica (Bb) Canine Parainfluenza virus (CPi)Use from 6 weeks of ageAnnual revaccinationProvides convenience of administration for fractious dogsChallenge trial demonstrated significant protection against Bb and CPi13 Can be used as a diluent to reconstitute Nobivac DHP to permit administration of a single C5 vaccinationTechnical ServicesExperienced veterinarians are available to provide technical support for your practice for Intervet/Schering-Plough s extensive product range.

10 1800 033 461 Call to speak to one of our Technical Services VeterinariansServices and advice include: Vaccination protocols Questions re label claims Monitoring of post-registration product performance Product complaint investigationsPREMIUMP arvoProtectionNobivac KCNobivac Bb/PiINTRANASALC anine Cough VACCINEINJECTABLEC anine Cough VaccineVACCINATIoN PRogRAM foR Nobivac KCPrimary vaccination in dogsA single dose of Nobivac KC administered to dogs 4 weeks of ageAnnual revaccination is recommendedVACCINATIoN PRogRAM foR Nobivac Bb/PiPrimary vaccination in dogs2 doses of Nobivac Bb/Pi at an interval of one


Related search queries